Research led by the Dana Farber Cancer Institute, Massachusetts, performed a secondary analysis of the Dana-Farber Cancer Institute 05-043 trial. In the paper, "Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Canc…

Comments

You must log in or register to comment.

(._.)

There's nothing here…

31 points (+31, −0)

Short URL:

http://blurb.social/84814

Health

Welcome to /f/health! This blurb is dedicated to all aspects of well-being. Join discussions on physical and mental health, nutrition, fitness, and medical advancements. Our rules: 1. Be respectful. 2. Stay on topic. 3. Provide reliable sources. 4. Avoid medical advice. 5. No self-diagnosis or promotion. Engage in informed discussions and explore the world of health with us!

Created June 22, 2023
Subscribe via RSS

Moderators

joeyrobert

See full list